Practical tools for people considering or researching psychedelic therapy: a decision-tree quiz, provider directories, a retreat finder, and a state-by-state legal status lookup.
A short, client-side decision tree that takes your goals, medical considerations, and legal constraints and suggests which therapy the evidence and access landscape supports exploring first. Not medical advice.
Decision pathA practical next-step guide for treatment-resistant depression: compare Spravato, IV/IM ketamine, at-home ketamine, psilocybin trials, and Oregon/Colorado psilocybin services by legality, insurance, evidence, and what to ask at the first appointment.
Safety checklistA safety-first guide to what is actually available at home: compounded oral/sublingual ketamine via telehealth, why Spravato is never take-home, what remote integration can and cannot do, and when at-home treatment is the wrong starting point.
Provider directoryCurated directory of US ketamine therapy providers — at-home telehealth programs, in-clinic IV/IM infusion networks, and the Spravato (esketamine) REMS network — with vetting guidance.
Provider directoryA curated meta-directory of the established psychedelic-therapist training programs (Fluence, CIIS, Polaris, IPI, Naropa, Sage, MAPS) whose alumni directories are the credible starting points.
Retreat directoryOregon Measure 109 and Colorado Prop 122 licensed service centers, plus the more medically-structured international operators for ayahuasca, ibogaine, and 5-MeO-DMT. Includes a retreat vetting checklist.
Booking checklistStep-by-step checklist for booking legal psilocybin services: verify Oregon or Colorado licenses, distinguish legal service centers from decriminalized possession, estimate total cost, screen facilitators, and plan preparation and integration.
Legal referencePlain-English reference for where each state stands on therapeutic access, decriminalization, and active legislation. Filterable by reform type.
Legal referenceNational overview of where every US state stands on psilocybin, MDMA, DMT, ibogaine, and ketamine. Four-tier ranking, clickable state grid, and 2026 reform watchlist.
Research volunteer guideHow to find and apply for psychedelic clinical trials: psilocybin, MDMA, ibogaine, DMT, and ketamine. Registry links, institution-specific portals, eligibility criteria, what participation involves, and how participants are protected.
Readiness assessmentA 12-question self-assessment that scores your readiness for a psychedelic ceremony across medical, psychological, logistical, and integration dimensions. Not a clearance, not medical advice.
Trauma referencePick a common trigger (criticism, abandonment, conflict, shame) and see the four F's response it usually maps to, what wound it points to, and the integration practices that support healing.
Safety screenerAn interactive screener: enter your prescriptions and supplements and see typical clinical-trial washout windows and the high-risk combinations. Educational only — always coordinate with your prescriber.
Recent briefings on psychedelic research, law, and policy.
Study shows electrical stimulation mimics ketamine effects in neurons, suggesting potential non-drug therapies for depression.
Aug 01, 2026
A systematic review finds neuroimaging can predict ketamine treatment response, aiding personalized psychedelic therapies.
Jul 15, 2026
A French study is testing psilocybin from Red Light Holland, blending research and industry to explore brain effects.
Jun 08, 2026
A pilot trial of standardized psychedelic therapy shows promise for treating clinical depression, potentially influencing future treatment protocols.
Jun 08, 2026
A new hypothesis suggests psilocybin may influence ADHD by altering neuroplasticity, but further research is needed.
Jun 05, 2026
Get the daily briefing in your inbox
Law, clinical science, and policy signal on psychedelic research — on our publish cadence. Start at the The Psychedelic Journal homepage.
Subscribe freeSuggest a tool, topic, or improvement that would make this site more useful.